According to Agile Therapeutics
's latest financial reports the company has $2.87 M in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $5.24 M | -72.6% |
2021-12-31 | $19.14 M | -64.86% |
2020-12-31 | $54.47 M | 57.98% |
2019-12-31 | $34.47 M | 339.17% |
2018-12-31 | $7.85 M | -78.16% |
2017-12-31 | $35.95 M | -26.25% |
2016-12-31 | $48.75 M | 41.74% |
2015-12-31 | $34.39 M | -14.4% |
2014-12-31 | $40.18 M | 1795.69% |
2013-12-31 | $2.11 M | -89.41% |
2012-12-31 | $20.01 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $22.92 B | 797,916.01% | ๐บ๐ธ USA |
Pfizer PFE | $12.69 B | 441,598.57% | ๐บ๐ธ USA |
Merck MRK | $7.09 B | 246,784.79% | ๐บ๐ธ USA |
TherapeuticsMD TXMD | $10.16 M | 253.85% | ๐บ๐ธ USA |
Antares Pharma ATRS | N/A | N/A | ๐บ๐ธ USA |